Author:
Belansky Julia,Yelin Dvir
Abstract
AbstractArtificial cell fusion often serves as a valuable tool for studying different applications in biology and medicine, including natural development, immune response, cancer metastasis and production of therapeutic molecules. Plasmonic cell fusion, a technique that uses specific cell labeling by gold nanoparticles and resonant femtosecond pulse irradiation for fusing neighboring cells, has been demonstrated useful for such applications, allowing high cell specificity and an overall low toxicity. Despite these advantages, the numerous experimental factors contributing to plasmonic fusion have often led to subpar fusion efficiencies, requiring repeated experiments and extensive calibration protocols for achieving optimal results. In this work we present a study that aims to improve the overall performance of plasmonic cell fusion in terms of fusion efficiency and cell viability. By varying the pulse fluence, nanoparticle concentration, incubation times, and culture handling protocols, we demonstrate up to 100% fusion of malignant epithelial cells across the entire irradiated area of the culture. We also show that some of the smaller cells may stay viable for up to several days. The results would allow plasmonic fusion to play a key role in numerous studies and applications that require specific, high-efficiency cell–cell fusion.
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Yokoyama, W. M. et al. Production of monoclonal antibodies. Curr. Protoc. Immunol. 102, 2–5 (2013).
2. Kennett, R. H. & MacKearn, T. J. Monoclonal antibodies (Springer, Berlin, 1982).
3. Dale, B. & Elder, K. In vitro fertilization (Cambridge University Press, Cambridge, 1997).
4. Rosenblatt, J., Kufe, D. & Avigan, D. Dendritic cell fusion vaccines for cancer immunotherapy. Expert Opin. Biol. Ther. 5, 703–715 (2005).
5. Saxena, M. & Bhardwaj, N. Re-emergence of dendritic cell vaccines for cancer treatment. Trends Cancer 4, 119–137 (2018).